دورية أكاديمية
أعرض في EDS

Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study.

التفاصيل البيبلوغرافية
العنوان: Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study.
المؤلفون: Allen RJ; Department of Health Sciences, University of Leicester, Leicester, UK. Electronic address: rja34@leicester.ac.uk., Oldham JM; Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA., Jenkins DA; Division of Informatics, Imaging & Data Sciences, University of Manchester, Manchester, UK., Leavy OC; Department of Health Sciences, University of Leicester, Leicester, UK., Guillen-Guio B; Department of Health Sciences, University of Leicester, Leicester, UK., Melbourne CA; Department of Health Sciences, University of Leicester, Leicester, UK., Ma SF; Division of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, VA, USA., Jou J; Department of Surgery, University of Illinois College of Medicine at Peoria, Peoria, IL, USA., Kim JS; Division of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, VA, USA., Fahy WA; Discovery Medicine, GlaxoSmithKline, Stevenage, UK., Oballa E; Discovery Medicine, GlaxoSmithKline, Stevenage, UK., Hubbard RB; Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK., Navaratnam V; Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK; Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, QLD, Australia., Braybrooke R; Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK; National Institute for Health Research, Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK., Saini G; Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK., Roach KM; Department of Respiratory Sciences, University of Leicester, Glenfield Hospital, Leicester, UK., Tobin MD; Department of Health Sciences, University of Leicester, Leicester, UK., Hirani N; Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK., Whyte MKB; Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK., Kaminski N; Section of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA., Zhang Y; Division of Pulmonary, Allergy and Critical Care Medicine, The University of Pittsburgh, Pittsburgh, PA, USA., Martinez FJ; Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA., Linderholm AL; Department of Internal Medicine, University of California Davis, Davis, CA, USA., Adegunsoye A; Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL, USA., Strek ME; Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL, USA., Maher TM; National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, London, UK; Division of Pulmonary and Critical Care Medicine, University of Southern California, Los Angeles, CA, USA., Molyneaux PL; National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, London, UK., Flores C; Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain; CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain; Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife, Spain., Noth I; Division of Pulmonary & Critical Care Medicine, University of Virginia, Charlottesville, VA, USA., Gisli Jenkins R; National Heart and Lung Institute, Imperial College London, London, UK., Wain LV; Department of Health Sciences, University of Leicester, Leicester, UK; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
مؤلفون مشاركون: CleanUP-IPF Investigators of the Pulmonary Trials Cooperative
المصدر: The Lancet. Respiratory medicine [Lancet Respir Med] 2023 Jan; Vol. 11 (1), pp. 65-73. Date of Electronic Publication: 2022 Aug 16.
نوع المنشور: Meta-Analysis; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Kidlington, Oxford Elsevier, [2013]-
مواضيع طبية MeSH: Genome-Wide Association Study* , Idiopathic Pulmonary Fibrosis*/diagnosis, Humans ; Lung ; Vital Capacity ; Lung Volume Measurements
مستخلص: Background: Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease characterised by progressive scarring leading to alveolar stiffness, reduced lung capacity, and impeded gas transfer. We aimed to identify genetic variants associated with declining lung capacity or declining gas transfer after diagnosis of IPF.
Methods: We did a genome-wide meta-analysis of longitudinal measures of forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) in individuals diagnosed with IPF. Individuals were recruited to three studies between June, 1996, and August, 2017, from across centres in the US, UK, and Spain. Suggestively significant variants were investigated further in an additional independent study (CleanUP-IPF). All four studies diagnosed cases following American Thoracic Society/European Respiratory Society guidelines. Variants were defined as significantly associated if they had a meta-analysis p<5 × 10 -8 when meta-analysing across all discovery and follow-up studies, had consistent direction of effects across all four studies, and were nominally significant (p<0·05) in each study.
Findings: 1329 individuals with a total of 5216 measures were included in the FVC analysis. 975 individuals with a total of 3361 measures were included in the DLCO analysis. For the discovery genome-wide analyses, 7 611 174 genetic variants were included in the FVC analysis and 7 536 843 in the DLCO analysis. One variant (rs115982800) located in an antisense RNA gene for protein kinase N2 (PKN2) showed a genome-wide significant association with FVC decline (-140 mL/year per risk allele [95% CI -180 to -100]; p=9·14 × 10 -12 ).
Interpretation: Our analysis identifies a genetic variant associated with disease progression, which might highlight a new biological mechanism for IPF. We found that PKN2, a Rho and Rac effector protein, is the most likely gene of interest from this analysis. PKN2 inhibitors are currently in development and signify a potential novel therapeutic approach for IPF.
Funding: Action for Pulmonary Fibrosis, Medical Research Council, Wellcome Trust, and National Institutes of Health National Heart, Lung, and Blood Institute.
Competing Interests: Declaration of interests LVW reports research funding from GlaxoSmithKline and Orion Pharma, and consultancy for Galapagos, outside of the submitted work. JMO reports personal fees from Boehringer Ingelheim, Genentech, United Therapeutics, AmMax Bio, and Lupin Pharmaceuticals, outside of the submitted work. RGJ is a trustee of Action for Pulmonary Fibrosis and reports personal fees from AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daewoong, Galapagos, Galecto, GlaxoSmithKline, Heptares, NuMedii, PatientMPower, Pliant, Promedior, Redx, Resolution Therapeutics, Roche, Veracyte, and Vicore, outside of the submitted work. AA reports personal fees from Boehringer Ingelheim and Genentech, outside of the submitted work. NK served as a consultant to Biogen, Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, TheraVance, Indalo, LifeMax, Three Lake Partners, Optikira, AstraZeneca, Rohbar, Veracyte, Augmanity, Gilead, Chiesi, Arrowhead, CSL-Behring, Galapagos, and Thyron over the past 3 years; reports Equity in Pliant and Thyron; reports being a scientific founder of Thyron; grants from Veracyte, Boehringer Ingelheim, Bristol Myers Squibb, and the Three Lakes Foundation; non-financial support from MiRagen and AstraZeneca; and has intellectual property on novel biomarkers and therapeutics in idiopathic pulmonary fibrosis licensed to Biotech. MDT reports grants or contracts from research collaborations with GlaxoSmithKline and Orion Pharma. RBH reports grants or contracts from Galapagos for serving on a trial adjudication outcome committee for an IPF trial, from AstraZeneca for serving on a COVID-19 vaccine safety committee, and from Boehringer Ingelheim for an IPF service provision consultation. WAF and EO are employees of GlaxoSmithKline. All other authors declare no competing interests.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
التعليقات: Comment in: Lancet Respir Med. 2023 Jan;11(1):5-6. (PMID: 35985356)
References: Nucleic Acids Res. 2021 Jan 8;49(D1):D1311-D1320. (PMID: 33045747)
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33. (PMID: 27322403)
Ned Tijdschr Geneeskd. 2008 Mar 1;152(9):518-9. (PMID: 18389888)
Hum Genet. 2022 Aug;141(8):1431-1447. (PMID: 35147782)
Genome Biol. 2016 Jun 06;17(1):122. (PMID: 27268795)
Nat Genet. 2013 Jun;45(6):613-20. (PMID: 23583980)
Twin Res Hum Genet. 2015 Feb;18(1):86-91. (PMID: 25518859)
Cell Rep. 2022 Jan 25;38(4):110227. (PMID: 35081338)
Nature. 2017 Oct 11;550(7675):204-213. (PMID: 29022597)
Bioinformatics. 2017 Dec 01;33(23):3793-3795. (PMID: 28582503)
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D514-7. (PMID: 15608251)
Nucleic Acids Res. 2014 Jan;42(Database issue):D802-9. (PMID: 24194600)
Eur Respir J. 2019 Apr 11;53(4):. (PMID: 30635297)
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. (PMID: 30168753)
Thorax. 2022 Aug;77(8):829-833. (PMID: 35688625)
Mol Cell Biol. 1997 Apr;17(4):2247-56. (PMID: 9121475)
Am J Respir Crit Care Med. 2020 Mar 1;201(5):564-574. (PMID: 31710517)
Nat Genet. 2016 Oct;48(10):1279-83. (PMID: 27548312)
Bioorg Med Chem Lett. 2020 Apr 15;30(8):127040. (PMID: 32085971)
Respirology. 2009 Sep;14(7):917-33. (PMID: 19740254)
Lancet Respir Med. 2017 Nov;5(11):869-880. (PMID: 29066090)
Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):743-7. (PMID: 9517585)
Cell Rep. 2016 Jan 26;14(3):440-448. (PMID: 26774483)
N Engl J Med. 2018 May 10;378(19):1811-1823. (PMID: 29742380)
Cell Rep Med. 2020 Oct 29;1(8):100137. (PMID: 33294858)
JAMA. 2021 May 11;325(18):1841-1851. (PMID: 33974018)
PLoS One. 2013 Apr 04;8(4):e60210. (PMID: 23593175)
Bioinformatics. 2010 Sep 1;26(17):2190-1. (PMID: 20616382)
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. (PMID: 21471066)
Nature. 2015 Oct 1;526(7571):68-74. (PMID: 26432245)
Bioinformatics. 2010 Sep 15;26(18):2336-7. (PMID: 20634204)
Commun Biol. 2021 Mar 23;4(1):392. (PMID: 33758299)
Nat Genet. 2015 Aug;47(8):856-60. (PMID: 26121088)
Nature. 2021 Sep;597(7877):527-532. (PMID: 34375979)
Clin Med Insights Circ Respir Pulm Med. 2016 Dec 08;9(Suppl 1):179-185. (PMID: 27980445)
JAMA. 2013 Jun 5;309(21):2232-9. (PMID: 23695349)
Lancet Respir Med. 2013 Jun;1(4):309-317. (PMID: 24429156)
N Engl J Med. 2011 Apr 21;364(16):1503-12. (PMID: 21506741)
Ann Am Thorac Soc. 2019 Feb;16(2):175-181. (PMID: 30540921)
معلومات مُعتمدة: MC_PC_17228 United Kingdom MRC_ Medical Research Council; R01 HL127349 United States HL NHLBI NIH HHS; 221680/Z/20/Z United Kingdom WT_ Wellcome Trust; R01 HL130796 United States HL NHLBI NIH HHS; K23 HL138190 United States HL NHLBI NIH HHS; U01 HL145567 United States HL NHLBI NIH HHS; MC_QA137853 United Kingdom MRC_ Medical Research Council; R01 HL141852 United States HL NHLBI NIH HHS; MC_PC_19004 United Kingdom MRC_ Medical Research Council; MR/V00235X/1 United Kingdom MRC_ Medical Research Council; R21 HL079394 United States HL NHLBI NIH HHS; K23 HL146942 United States HL NHLBI NIH HHS; R56 HL158935 United States HL NHLBI NIH HHS; UH2 HL123886 United States HL NHLBI NIH HHS; UG3 HL145266 United States HL NHLBI NIH HHS; United Kingdom WT_ Wellcome Trust; R21 HL161723 United States HL NHLBI NIH HHS
تواريخ الأحداث: Date Created: 20220819 Date Completed: 20221227 Latest Revision: 20240102
رمز التحديث: 20240102
مُعرف محوري في PubMed: PMC10077113
DOI: 10.1016/S2213-2600(22)00251-X
PMID: 35985358
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-2619
DOI:10.1016/S2213-2600(22)00251-X